Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

Rating neurologic impairment in multiple sclerosis

1983 • 14,011 citations

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

2005 • 4,912 citations

Defining the clinical course of multiple sclerosis

1996 • 3,606 citations

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

2010 • 2,531 citations

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

2010 • 2,146 citations

Diagnostic criteria for multiple sclerosis

2001 • 1,337 citations

Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

2010 • 739 citations

FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P ₁ ) modulation

2010 • 557 citations

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

2009 • 429 citations

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis

2008 • 326 citations

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

2013 • 193 citations

Assessing disability progression with the Multiple Sclerosis Functional Composite

2009 • 99 citations

Fingolimod for Multiple Sclerosis: Mechanism of Action, Clinical Outcomes, and Future Directions

2011 • 66 citations

EDSS variability before randomization may limit treatment discovery in primary progressive MS

2012 • 19 citations